Clinical trial
Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer
NCT00275951 · National Taiwan University Hospital, Other · Completed
Key facts
| NCT number | NCT00275951 |
|---|---|
| Title | Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer |
| Official title | Phase II Study of Cetuximab Plus P-HDFL(Cisplatin and Weekly 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin)for the First-line Treatment of Advanced Gastric Cancer |
| Acronym | FLAG |
| Lead sponsor | National Taiwan University Hospital, Other |
| Collaborators | Taipei Veterans General Hospital, Taiwan National Health Research Institutes, Taiwan Chang Gung Memorial Hospital Tri-Service General Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | Cetuximab Plus P-HDFL |
| Enrollment | 39 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jan 12, 2006 |
| Last update posted | Nov 16, 2012 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: